CD274 and esophageal squamous cell carcinoma: With 80% price reduction of nivolumab and ipilimumab, the ICER ($29,649.50/QALY) of nivolumab plus ipilimumab versus chemotherapy was below the WTP threshold in the treatment of PD-L1-positive advanced ESCC patients.